Pre-existing immunity against Ad vectors: Humoral, cellular, and innate response, what's important?

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 10, 2014, Pages 2875-2884

  Fausther Bovendo, Hugues ^a,b   Kobinger, Gary P ^a,b  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Adenovirus vectors; Cellular responses; Humoral responses; Innate immunity; Pre existing immunity

Indexed keywords

ADENOVIRUS VECTOR; NEUTRALIZING ANTIBODY; INTERFERON; VIRUS ANTIBODY;

ADENOVIRIDAE; ANTIGEN EXPRESSION; CELLULAR IMMUNITY; DRUG ADMINISTRATION; HUMAN; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOSTIMULATION; INFECTION RESISTANCE; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; NATURAL KILLER CELL; NONHUMAN; REVIEW; SEROPREVALENCE; T LYMPHOCYTE; VIRUS NEUTRALIZATION; ADENOVIRUS INFECTIONS, HUMAN; HUMAN ADENOVIRUS C; IMMUNIZATION; IMMUNOLOGY; PROCEDURES;

ADENOVIRUS INFECTIONS, HUMAN; ADENOVIRUSES, HUMAN; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNITY, INNATE; IMMUNIZATION; INTERFERON TYPE I; KILLER CELLS, NATURAL; T-LYMPHOCYTES;

EID: 84921413907     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.29594     Document Type: Review

References (102)

1. Amanna IJ, Messaoudi I, Slifka MK. Protective immunity following vaccination: how is it defined? Hum Vaccin 2008; 4:316-9; PMID:18398296; http://dx.doi.org/10.4161/hv.4.4.5751
2. Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR, Orenstein WA. Measles antibody: reevaluation of protective titers. J Infect Dis 1990; 162:1036-42; PMID:2230231; http://dx.doi.org/10.1093/infdis/162.5.1036
3. Mason RA, Tauraso NM, Spertzel RO, Ginn RK. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol 1973; 25:539-44; PMID:4633476
4. Tatsis N, Ertl HCJ. Adenoviruses as vaccine vectors. Mol Ther 2004; 10:616-29; PMID:15451446; http://dx.doi.org/10.1016/j.ymthe.2004.07.013
5. Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, et al.; VRC 205 Study Team. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010; 29:304-13; PMID:21034824; http://dx.doi.org/10.1016/j.vaccine.2010.10.037
6. Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH, et al.; HVTN 503/Phambili study team. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 2011; 11:507-15; PMID:21570355; http://dx.doi.org/10.1016/S1473-3099(11)70098-6
7. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, et al.; Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-93; PMID:19012954; http://dx.doi.org/10.1016/S0140-6736(08)61591-3
8. Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2007 - an update. J Gene Med 2007; 9:833-42; PMID:17721874; http://dx.doi.org/10.1002/jgm.1100
9. Kremer EJ, Perricaudet M. Adenovirus and adeno-associated virus mediated gene transfer. Br Med Bull 1995; 51:31-44; PMID:7767647
10. Echavarría M. Adenoviruses in immunocompromised hosts. Clin Microbiol Rev 2008; 21:704-15; PMID:18854488; http://dx.doi.org/10.1128/CMR.00052-07
11. Nwanegbo E, Vardas E, Gao W, Whittle H, Sun H, Rowe D, Robbins PD, Gambotto A. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 2004; 11:351-7; PMID:15013987
12. Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 2007; 81:4654-63; PMID:17329340; http://dx.doi.org/10.1128/JVI.02696-06
13. Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, Novitsky V, Mbewe B, Pitisuttithum P, Schechter M, Vardas E, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 2010; 28:950-7; PMID:19925902; http://dx.doi.org/10.1016/j.vaccine.2009.10.145
14. Chen H, Xiang ZQ, Li Y, Kurupati RK, Jia B, Bian A, Zhou DM, Hutnick N, Yuan S, Gray C, et al. Adeno-virus-based vaccines: comparison of vectors from three species of adenoviridae. J Virol 2010; 84:10522-32; PMID:20686035; http://dx.doi.org/10.1128/JVI.00450-10
15. Rahman A, Tsai V, Goudreau A, Shinoda JY, Wen SF, Ramachandra M, Ralston R, Maneval D, LaFace D, Shabram P. Specific depletion of human anti-adenovirus antibodies facilitates transduction in an in vivo model for systemic gene therapy. Mol Ther 2001; 3:768-78; PMID:11356081; http://dx.doi.org/10.1006/mthe.2001.0316
16. Sumida SM, Truitt DM, Kishko MG, Arthur JC, Jackson SS, Gorgone DA, Lifton MA, Koudstaal W, Pau MG, Kostense S, et al. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol 2004; 78:2666-73; PMID:14990686; http://dx.doi.org/10.1128/JVI.78.6.2666-2673.2004
17. Gahéry-Ségard H, Farace F, Godfrin D, Gaston J, Lengagne R, Tursz T, Boulanger P, Guillet JG. Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J Virol 1998; 72:2388-97; PMID:9499099
18. Roy S, Clawson DS, Calcedo R, Lebherz C, Sanmiguel J, Wu D, Wilson JM. Use of chimeric adenoviral vectors to assess capsid neutralization determinants. Virology 2005; 333:207-14; PMID:15721355; http://dx.doi.org/10.1016/j.virol.2004.12.029
19. Pichla-Gollon SL, Drinker M, Zhou X, Xue F, Rux JJ, Gao GP, Wilson JM, Ertl HC, Burnett RM, Bergelson JM. Structure-based identification of a major neutralizing site in an adenovirus hexon. J Virol 2007; 81:1680-9; PMID:17108028; http://dx.doi.org/10.1128/JVI.02023-06
20. Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers JH, Addo MM, Lockman S, Peter T, Peyerl FW, Kishko MG, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 2005; 174:7179-85; PMID:15905562; http://dx.doi.org/10.4049/jimmunol.174.11.7179
21. Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, Ewald BA, Liu J, Thorner AR, Swanson PE, Gorgone DA, et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006; 441:239-43; PMID:16625206; http://dx.doi.org/10.1038/nature04721
22. Roy S, Shirley PS, McClelland A, Kaleko M. Circumvention of immunity to the adenovirus major coat protein hexon. J Virol 1998; 72:6875-9; PMID:9658137
23. Gall J, Kass-Eisler A, Leinwand L, Falck-Pedersen E. Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J Virol 1996; 70:2116-23; PMID:8642632
24. Toogood CI, Crompton J, Hay RT. Antipeptide antisera define neutralizing epitopes on the adenovirus hexon. J Gen Virol 1992; 73:1429-35; PMID:1376769; http://dx.doi.org/10.1099/0022-1317-73-6-1429
25. Moffatt S, Hays J, HogenEsch H, Mittal SK. Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy. Virology 2000; 272:159-67; PMID:10873758; http://dx.doi.org/10.1006/viro.2000.0350
26. Pichla-Gollon SL, Lin SW, Hensley SE, Lasaro MO, Herkenhoff-Haut L, Drinker M, Tatsis N, Gao GP, Wilson JM, Ertl HC, et al. Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo. J Virol 2009; 83:5567-73; PMID:19279092; http://dx.doi.org/10.1128/JVI.00405-09
27. Olive M, Eisenlohr L, Flomenberg N, Hsu S, Flomenberg P. The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope. Hum Gene Ther 2002; 13:1167-78; PMID:12133270; http://dx.doi.org/10.1089/104303402320138952
28. Leen AM, Sili U, Vanin EF, Jewell AM, Xie W, Vignali D, Piedra PA, Brenner MK, Rooney CM. Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroupspecific CD8+ T cells. Blood 2004; 104:2432-40; PMID:15265797; http://dx.doi.org/10.1182/blood-2004-02-0646
29. Tang J, Olive M, Pulmanausahakul R, Schnell M, Flomenberg N, Eisenlohr L, Flomenberg P. Human CD8+ cytotoxic T cell responses to adenovirus capsid proteins. Virology 2006; 350:312-22; PMID:16499941; http://dx.doi.org/10.1016/j.virol.2006.01.024
30. Veltrop-Duits LA, Heemskerk B, Sombroek CC, van Vreeswijk T, Gubbels S, Toes RE, Melief CJ, Franken KL, Havenga M, van Tol MJ, et al. Human CD4+ T cells stimulated by conserved adenovirus 5 hexon peptides recognize cells infected with different species of human adenovirus. Eur J Immunol 2006; 36:2410-23; PMID:16933360; http://dx.doi.org/10.1002/eji.200535786
31. Leen AM, Christin A, Khalil M, Weiss H, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol 2008; 82:546-54; PMID:17942545; http://dx.doi.org/10.1128/JVI.01689-07
32. Heemskerk B, Veltrop-Duits LA, van Vreeswijk T, ten Dam MM, Heidt S, Toes RE, van Tol MJ, Schilham MW. Extensive cross-reactivity of CD4 +adenovirus-specific T cells: implications for immunotherapy and gene therapy. J Virol 2003; 77:6562-6; PMID:12743315; http://dx.doi.org/10.1128/JVI.77.11.6562-6566.2003
33. Calcedo R, Vandenberghe LH, Roy S, Somanathan S, Wang L, Wilson JM. Host immune responses to chronic adenovirus infections in human and nonhuman primates. J Virol 2009; 83:2623-31; PMID:19116257; http://dx.doi.org/10.1128/JVI.02160-08
34. Hutnick NA, Carnathan D, Demers K, Makedonas G, Ertl HC, Betts MR. Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive. Vaccine 2010; 28:1932-41; PMID:20188249; http://dx.doi.org/10.1016/j.vaccine.2009.10.091
35. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999; 6:1574-83; PMID:10490767; http://dx.doi.org/10.1038/sj.gt.3300994
36. O'Leary JG, Goodarzi M, Drayton DL, von Andrian UH. T cell- and B cell-independent adaptive immunity mediated by natural killer cells. Nat Immunol 2006; 7:507-16; PMID:16617337; http://dx.doi.org/10.1038/ni1332
37. Cooper MA, Elliott JM, Keyel PA, Yang L, Carrero JA, Yokoyama WM. Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci U S A 2009; 106:1915-9; PMID:19181844; http://dx.doi.org/10.1073/pnas.0813192106
38. Hartman ZC, Appledorn DM, Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res 2008; 132:1-14; PMID:18036698; http://dx.doi.org/10.1016/j.virusres.2007.10.005
39. Thaci B, Ulasov IV, Wainwright DA, Lesniak MS. The challenge for gene therapy: innate immune response to adenoviruses. Oncotarget 2011; 2:113-21; PMID:21399236
40. Fejer G, Freudenberg M, Greber UF, Gyory I. Adeno-virus-triggered innate signalling pathways. Eur J Microbiol Immunol (Bp) 2011; 1:279-88; PMID:24516734; http://dx.doi.org/10.1556/EuJMI.1.2011.4.3
41. Doronin K, Flatt JW, Di Paolo NC, Khare R, Kalyuzhniy O, Acchione M, Sumida JP, Ohto U, Shimizu T, Akashi-Takamura S, et al. Coagulation factor X activates innate immunity to human species C adenovirus. Science 2012; 338:795-8; PMID:23019612; http://dx.doi.org/10.1126/science.1226625
42. Zhu J, Huang X, Yang Y. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J Virol 2007; 81:3170-80; PMID:17229689; http://dx.doi.org/10.1128/JVI.02192-06
43. Fejer G, Drechsel L, Liese J, Schleicher U, Ruzsics Z, Imelli N, Greber UF, Keck S, Hildenbrand B, Krug A, et al. Key role of splenic myeloid DCs in the IFN-alphabeta response to adenoviruses in vivo. PLoS Pathog 2008; 4:e1000208; PMID:19008951; http://dx.doi.org/10.1371/journal.ppat.1000208
44. Di Paolo NC, Miao EA, Iwakura Y, Murali-Krishna K, Aderem A, Flavell RA, Papayannopoulou T, Shayakhmetov DM. Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo. Immunity 2009; 31:110-21; PMID:19576795; http://dx.doi.org/10.1016/j.immuni.2009.04.015
45. Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D, Honko A, Johnson J, Mulangu S, Pau MG, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol 2011; 85:4222-33; PMID:21325402; http://dx.doi.org/10.1128/JVI.02407-10
46. Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A, Siani L, Naddeo M, Grazioli F, Esposito ML, et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 2012; 4:ra2; PMID:22218691; http://dx.doi.org/10.1126/scitranslmed.3002925
47. Teigler JE, Iampietro MJ, Barouch DH. Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys. J Virol 2012; 86: 9590-8; PMID:22787208; http://dx.doi.org/10.1128/JVI.00740-12
48. Johnson MJ, Björkström NK, Petrovas C, Liang F, Gall JG, Loré K, Koup RA. Type I interferon-dependent activation of NK cells by rAd28 or rAd35, but not rAd5, leads to loss of vector-insert expression. Vaccine 2014; 32:717-24; PMID:24325826; http://dx.doi.org/10.1016/j.vaccine.2013.11.055
49. Hensley SE, Giles-Davis W, McCoy KC, Weninger W, Ertl HCJ. Dendritic cell maturation, but not CD8+ T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors. J Immunol 2005; 175:6032-41; PMID:16237098; http://dx.doi.org/10.4049/jimmunol.175.9.6032
50. Hensley SE, Cun AS, Giles-Davis W, Li Y, Xiang Z, Lasaro MO, Williams BR, Silverman RH, Ertl HC. Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector. Mol Ther 2007; 15:393-403; PMID:17235319; http://dx.doi.org/10.1038/sj.mt.6300024
51. Zhu J, Huang X, Yang Y. A critical role for type I IFN-dependent NK cell activation in innate immune elimination of adenoviral vectors in vivo. Mol Ther 2008; 16:1300-7; PMID:18443600; http://dx.doi.org/10.1038/mt.2008.88
52. Mitrović M, Arapović J, Traven L, Krmpotić A, Jonjić S. Innate immunity regulates adaptive immune response: lessons learned from studying the interplay between NK and CD8+ T cells during MCMV infection. Med Microbiol Immunol 2012; 201:487-95; PMID:22965169; http://dx.doi.org/10.1007/s00430-012-0263-0
53. Welsh RM, Waggoner SN. NK cells controlling virus-specific T cells: Rheostats for acute vs. persistent infections. Virology 2013; 435:37-45; PMID:23217614; http://dx.doi.org/10.1016/j.virol.2012.10.005
54. Keefer MC, Gilmour J, Hayes P, Gill D, Kopycinski J, Cheeseman H, Cashin-Cox M, Naarding M, Clark L, Fernandez N, et al. A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One 2012; 7:e41936; PMID:22870265; http://dx.doi.org/10.1371/journal.pone.0041936
55. Baden LR, Walsh SR, Seaman MS, Tucker RP, Krause KH, Patel A, Johnson JA, Kleinjan J, Yanosick KE, Perry J, et al. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis 2013; 207:240-7; PMID:23125444; http://dx.doi.org/10.1093/infdis/jis670
56. Barouch DH, Liu J, Peter L, Abbink P, Iampietro MJ, Cheung A, Alter G, Chung A, Dugast AS, Frahm N, et al. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J Infect Dis 2013; 207:248-56; PMID:23125443; http://dx.doi.org/10.1093/infdis/jis671
57. Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, Truitt DM, Sumida SM, Kishko MG, Arthur JC, et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 2004; 172:6290-7; PMID:15128818; http://dx.doi.org/10.4049/jimmunol.172.10.6290
58. Lemckert AAC, Sumida SM, Holterman L, Vogels R, Truitt DM, Lynch DM, Nanda A, Ewald BA, Gorgone DA, Lifton MA, et al. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol 2005; 79:9694-701; PMID:16014931; http://dx.doi.org/10.1128/JVI.79.15.9694-9701.2005
59. Nanda A, Lynch DM, Goudsmit J, Lemckert AA, Ewald BA, Sumida SM, Truitt DM, Abbink P, Kishko MG, Gorgone DA, et al. Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys. J Virol 2005; 79:14161-8; PMID:16254351; http://dx.doi.org/10.1128/JVI.79.22.14161-14168.2005
60. Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Béthune MP, Kostense S, Penders G, Helmus N, Koudstaal W, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003; 77:8263-71; PMID:12857895; http://dx.doi.org/10.1128/JVI.77.15.8263-8271.2003
61. Flomenberg P, Piaskowski V, Truitt RL, Casper JT. Characterization of human proliferative T cell responses to adenovirus. J Infect Dis 1995; 171: 1090-6; PMID:7751682; http://dx.doi.org/10.1093/infdis/171.5.1090
62. Jian L, Zhao Q, Zhang S, Huang W, Xiong Y, Zhou X, Jia B. The prevalence of neutralising antibodies to chimpanzee adenovirus type 6 and type 7 in healthy adult volunteers, patients with chronic hepatitis B and patients with primary hepatocellular carcinoma in China. Arch Virol 2014; 159:465-70; PMID:24057756; http://dx.doi.org/10.1007/s00705-013-1828-y
63. Kobinger GP, Feldmann H, Zhi Y, Schumer G, Gao G, Feldmann F, Jones S, Wilson JM. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 2006; 346:394-401; PMID:16356525; http://dx.doi.org/10.1016/j.virol.2005.10.042
64. Zhou D, Cun A, Li Y, Xiang Z, Ertl HCJ. A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus. Mol Ther 2006; 14:662-72; PMID:16797238; http://dx.doi.org/10.1016/j.ymthe.2006.03.027
65. Xiang ZQ, Greenberg L, Ertl HC, Rupprecht CE. Protection of non-human primates against rabies with an adenovirus recombinant vaccine. Virology 2014; 450-451:243-9; PMID:24503087; http://dx.doi.org/10.1016/j.virol.2013.12.029
66. Reyes-Sandoval A, Sridhar S, Berthoud T, Moore AC, Harty JT, Gilbert SC, Gao G, Ertl HC, Wilson JC, Hill AV. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur J Immunol 2008; 38:732-41; PMID:18266272; http://dx.doi.org/10.1002/eji.200737672
67. Reyes-Sandoval A, Berthoud T, Alder N, Siani L, Gilbert SC, Nicosia A, Colloca S, Cortese R, Hill AV. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun 2010; 78: 145-53; PMID:19858306; http://dx.doi.org/10.1128/IAI.00740-09
68. Warimwe GM, Lorenzo G, Lopez-Gil E, Reyes-Sandoval A, Cottingham MG, Spencer AJ, Collins KA, Dicks MD, Milicic A, Lall A, et al. Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice. Virol J 2013; 10:349; PMID:24304565; http://dx.doi.org/10.1186/1743-422X-10-349
69. Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, Meyer J, Huddart R, Smith K, Townsend R, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012; 4:ra1; PMID:22218690; http://dx.doi.org/10.1126/scitranslmed.3003155
70. Roy S, Vandenberghe LH, Kryazhimskiy S, Grant R, Calcedo R, Yuan X, Keough M, Sandhu A, Wang Q, Medina-Jaszek CA, et al. Isolation and characterization of adenoviruses persistently shed from the gastrointestinal tract of non-human primates. PLoS Pathog 2009; 5:e1000503; PMID:19578438; http://dx.doi.org/10.1371/journal.ppat.1000503
71. Xiang Z, Gao G, Reyes-Sandoval A, Cohen CJ, Li Y, Bergelson JM, Wilson JM, Ertl HC. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 2002; 76:2667-75; PMID:11861833; http://dx.doi.org/10.1128/JVI.76.6.2667-2675.2002
72. Bangari DS, Mittal SK. Development of nonhuman adenoviruses as vaccine vectors. Vaccine 2006; 24:849-62; PMID:16297508; http://dx.doi.org/10.1016/j.vaccine.2005.08.101
73. Hofmann C, Löser P, Cichon G, Arnold W, Both GW, Strauss M. Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo. J Virol 1999; 73:6930-6; PMID:10400791
74. Bangari DS, Shukla S, Mittal SK. Comparative transduction efficiencies of human and nonhuman adenoviral vectors in human, murine, bovine, and porcine cells in culture. Biochem Biophys Res Commun 2005; 327:960-6; PMID:15649439; http://dx.doi.org/10.1016/j.bbrc.2004.12.099
75. Sharma A, Tandon M, Ahi YS, Bangari DS, Vemulapalli R, Mittal SK. Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses. Gene Ther 2010; 17: 634-42; PMID:20164856; http://dx.doi.org/10.1038/gt.2010.1
76. Singh N, Pandey A, Jayashankar L, Mittal SK. Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. Mol Ther 2008; 16:965-71; PMID:18301400; http://dx.doi.org/10.1038/mt.2008.12
77. Patel A, Tikoo S, Kobinger G. A porcine adenovirus with low human seroprevalence is a promising alternative vaccine vector to human adenovirus 5 in an H5N1 virus disease model. PLoS One 2010; 5: e15301; PMID:21179494; http://dx.doi.org/10.1371/journal.pone.0015301
78. Wüest T, Both GW, Prince AM, Hofmann C, Löser P. Recombinant ovine atadenovirus induces a strong and sustained T cell response against the hepatitis C virus NS3 antigen in mice. Vaccine 2004; 22: 2717-21; PMID:15246602; http://dx.doi.org/10.1016/j.vaccine.2004.01.048
79. Xiang ZQ, Gao GP, Reyes-Sandoval A, Li Y, Wilson JM, Ertl HC. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol 2003; 77:10780-9; PMID:14512528; http://dx.doi.org/10.1128/JVI.77.20.10780-10789.2003
80. Richardson JS, Pillet S, Bello AJ, Kobinger GP. Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates. J Virol 2013; 87:3668-77; PMID:23302894; http://dx.doi.org/10.1128/JVI.02864-12
81. Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, Carbone FR. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat Immunol 2009; 10:524-30; PMID:19305395; http://dx.doi.org/10.1038/ni.1718
82. Gebhardt T, Mueller SN, Heath WR, Carbone FR. Peripheral tissue surveillance and residency by memory T cells. Trends Immunol 2013; 34:27-32; PMID:23036434; http://dx.doi.org/10.1016/j.it.2012.08.008
83. Krzysiek R, de Goër de Herve M-G, Yang H, Taoufik Y. Tissue Competence Imprinting and Tissue Residency of CD8 T Cells. Front Immunol 2013; 4:283; PMID:24062749; http://dx.doi.org/10.3389/fimmu.2013.00283
84. Jiang X, Clark RA, Liu L, Wagers AJ, Fuhlbrigge RC, Kupper TS. Skin infection generates non-migratorymemory CD8+ T(RM) cells providing global skin immunity. Nature 2012; 483:227-31; PMID:22388819; http://dx.doi.org/10.1038/nature10851
85. Mackay LK, Stock AT, Ma JZ, Jones CM, Kent SJ, Mueller SN, Heath WR, Carbone FR, Gebhardt T. Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc Natl Acad Sci U S A 2012; 109:7037-42; PMID:22509047; http://dx.doi.org/10.1073/pnas.1202288109
86. Gebhardt T, Whitney PG, Zaid A, Mackay LK, Brooks AG, Heath WR, Carbone FR, Mueller SN. Different patterns of peripheral migration by memory CD4+ and CD8+ T cells. Nature 2011; 477:216-9; PMID:21841802; http://dx.doi.org/10.1038/nature 10339
87. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, Wilson JM, Batshaw ML. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80:148-58; PMID:14567964; http://dx.doi.org/10.1016/j.ymgme.2003.08.016
88. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10:317-27; PMID:20414205; http://dx.doi.org/10.1038/nri2744
89. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science 2013; 341:1192-8; PMID:24031011; http://dx.doi.org/10.1126/science.1241145
90. Richardson JS, Abou MC, Tran KN, Kumar A, Sahai BM, Kobinger GP. Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs. J Infect Dis 2011; 204 (Suppl 3):S1032-42; PMID:21987739; http://dx.doi.org/10.1093/infdis/jir332
91. Woodland DL. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 2004; 25:98-104; PMID:15102369; http://dx.doi.org/10.1016/j.it.2003.11.009
92. Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol 2009; 21:346-51; PMID:19500964; http://dx.doi.org/10.1016/j.coi.2009.05.016
93. Gilbert SC, Schneider J, Hannan CM, Hu JT, Plebanski M, Sinden R, Hill AV. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 2002; 20:1039-45; PMID:11803063; http://dx.doi.org/10.1016/S0264-410X(01)00450-9
94. Barouch DH, McKay PF, Sumida SM, Santra S, Jackson SS, Gorgone DA, Lifton MA, Chakrabarti BK, Xu L, Nabel GJ, et al. Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol 2003; 77:8729-35; PMID:12885892; http://dx.doi.org/10.1128/JVI.77.16.8729-8735.2003
95. Park S-H, Yang SH, Lee CG, Youn JW, Chang J, Sung YC. Efficient induction of T helper 1 CD4+ T-cell responses to hepatitis C virus core and E2 by a DNA prime-adenovirus boost. Vaccine 2003; 21:4555-64; PMID:14575768; http://dx.doi.org/10.1016/S0264-410X(03)00499-7
96. Pinto AR, Fitzgerald JC, Giles-Davis W, Gao GP, Wilson JM, Ertl HC. Induction of CD8C T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J Immunol 2003; 171:6774-9; PMID:14662882; http://dx.doi.org/10.4049/jimmunol.171.12.6774
97. Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, Nabel GJ. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 2003; 77:799-803; PMID:12477888; http://dx.doi.org/10.1128/JVI.77.1.799-803.2003
98. Kibuuka H, Kimutai R, Maboko L, Sawe F, Schunk MS, Kroidl A, Shaffer D, Eller LA, Kibaya R, Eller MA, et al. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). J Infect Dis 2010; 201:600-7; PMID:20078213; http://dx.doi.org/10.1086/650299
99. McCoy K, Tatsis N, Korioth-Schmitz B, Lasaro MO, Hensley SE, Lin SW, Li Y, Giles-Davis W, Cun A, Zhou D, et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J Virol 2007; 81:6594-604; PMID:17428852; http://dx.doi.org/10.1128/JVI.02497-06
100. Ba L, Yi CE, Zhang L, Ho DD, Chen Z. Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus. Appl Microbiol Biotechnol 2007; 76:1131-6; PMID:17581748; http://dx.doi.org/10.1007/s00253-007-1073-y
101. Capone S, D'Alise AM, Ammendola V, Colloca S, Cortese R, Nicosia A, Folgori A. Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. Expert Rev Vaccines 2013; 12:379-93; PMID:23560919; http://dx.doi.org/10.1586/erv.13.15
102. Gudmundsdotter L, Nilsson C, Brave A, Hejdeman B, Earl P, Moss B, Robb M, Cox J, Michael N, Marovich M, et al. Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite preexisting vaccinia immunity. Vaccine 2009; 27:4468-74; PMID:19450644; http://dx.doi.org/10.1016/j.vaccine.2009.05.018